Here is a comment from Sinclair. [Sinclair notes that Life Biosciences expects to have three to five clinical programs in humans in 2019 from the various companies. “We have intentionally focused on early preclinical work because we were doing the land grab in the aging space. Many of the scientists’ work and IP were not publicly available, that’s why they are overall preclinical. We do have sights on clinical assets I can’t talk about yet.”] Maybe that is Prana assets, because the Prana board is also not talking. https://www.biospace.com/article/life-biosciences-a-new-paradigm-for-approaching-longevity-research/
PBT Price at posting:
4.0¢ Sentiment: None Disclosure: Not Held
